Purpose-To develop an imaging tool that enables the detection of malignant tissue with enhanced specificity using the exquisite spatial resolution of MRI.
INTRODUCTION
Molecular-genetic MRI uses reporter-imaging probe pairs that can generate MR contrast (1) . The goal of molecular-genetic MRI is to leverage the superior three-dimensional spatial resolution of MRI to develop reporter-based, targeted MRI systems. Many reporters have been identified as candidate MR contrast-generating genes. Those include: the βgalactosidase-Gd 3+ -containing galactopyranosyl ring reporter-probe pair for T 1 contrast (2); the tyrosinase-paramagnetic iron pair for T 2 contrast (3); the transferrin receptormonocrystalline iron oxide nanocompound pair for T 2 contrast (4); the ferritin and endogenous iron pair for T 2 contrast (5, 6) ; the Mag A-iron pair for T 2 contrast (7) ; and, the secreted alkaline phosphatase (SEAP)-phospho-rylated metalloporphyrin pair for T 1 contrast (8) . We have developed an artificial gene, the lysine-rich protein (LRP), as a reporter for chemical exchange saturation transfer (CEST) MRI (9) . The LRP provides a high density of amide protons, which enables detection by MRI without requiring administration of a cognate probe. LRP-expressing tumors in the mouse brain have been imaged by CEST MRI (9) .
For imaging reporter genes to be applied in a target-specific manner, they should either be delivered exclusively to their targets or expressed specifically within the target cells. The latter can be accomplished by using a target-selective promoter to drive the expression of a reporter following systemic delivery of a reporter plasmid. Many promoters of genes with elevated expression in human cancers have been examined as potential cancer-specific promoters, but most are active only in cancers of certain tissues of origin (10, 11) . The optimal promoters for cancer-specific, molecular-genetic imaging would be active in a variety of human cancers, while remaining minimally active or silent in normal tissues. We have identified a minimal promoter from a rodent gene, the progression elevated gene-3 (PEG-3 promoter), through subtraction hybridization while searching for genes involved in malignant transformation and tumor progression (12) . We found that the PEG-3 promoter behaves as a cancer-specific promoter as it is active in a variety of human cancers, including brain, prostate, breast, pancreatic, and skin cancers, with minimal activity in normal counterpart tissues (13) (14) (15) (16) . Tumor specificity of the PEG-3 promoter has been attributed to binding sites of two transcription factors, AP-1 and PEA-3 (or E1AF, the human homolog), which are reported to be overexpressed in human cancer cells (13) . Systemic delivery of the PEG-3 promoter-reporter plasmid followed by imaging with bioluminescence or single photon emission computed tomography (SPECT) enabled detection of micrometastases in experimental models of human breast cancer and melanoma (17) . However, bioluminescence imaging cannot extend beyond preclinical models and SPECT is fraught with relatively low spatial resolution. Accordingly we turned to MRI with the PEG-3 promoter to drive production of LRP in a cancer-specific manner with the high spatial resolution of this modality.
The LRP is based on CEST, a relatively new MR contrast mechanism (18) (19) (20) . CEST allows detection of bioorganic molecules, such as proteins (21, 22) , polysaccharides (23, 24) , metabolites (25) (26) (27) , enzyme substrates (28) (29) (30) (31) as well as injectable compounds (32) due to the exchange of MR-saturable, labile protons in these molecules with those of water. Here, we present a molecular-genetic imaging approach to detect tumor-specific gene expression in an animal model of glioma by using the MR reporter gene LRP and CEST MRI. The LRP was expressed under control of the tumor-specific PEG-3 promoter in rat 9L glioma cells (9L PEG-LRP ). 9L PEG-LRP cells transplanted to a mouse brain showed higher CEST contrast compared with that from similarly transplanted wild-type cells. Our results demonstrate the feasibility of using a CEST-based reporter gene under a tumor-specific promoter for detection of tumors in vivo with MRI.
METHODS

In Vitro Assessment of PEG-Promoter Activity
The dual-luciferase assay was carried out to measure promoter activities in rat 9L glioma cells. 9L cells were grown in RPMI 1640 supplemented with 10% fetal bovine serum and 1× penicillin and streptomycin in a humidified incubator (37°C, 5% CO 2 ). 9L cells were seeded in 24-well plates (1 × 10 5 cells per well). Forty-eight hours later, cells were transiently transfected with the following combination of plasmids using jetPRIME ® according to the manufacturer's instructions (Polyplus-Transfection Inc., Illkirch, France); (i) pPEG-Luc (17) + pGL4.74 (Promega, Madison, WI), (ii) pCMV-Tri (17) + pGL4.74, and (iii) pGL3-basic (Promega, Madison WI) + pGL4.74 with a 10:1 ratio for each preparation. pPEG-Luc possess PEG-3 promoter driven firefly luciferase (fLuc), pCMV-Tri has CMV promoter driven fLuc, and pGL3-basic plasmid has no promoter, serving as a promoterless control. pGL4.74 plasmid expresses Renilla luciferase (rLuc) to normalized the transfection efficiency. At 48 h post-transfection, fLuc activity was measured using the Dual-Luciferase ® Reporter Assay System (Promega). The fLuc activity was normalized to rLuc activity and total protein amount measured by the Coomasie ® protein assay reagent kit (Pierce Biotechnology, Rockford, IL).
Cloning of the Expression Constructs
The pMONO-neo-mcs vector was purchased from InvivoGen (San Diego, CA) and the ferritin heavy chain core promoter was replaced with the PEG-3 promoter to create pPEGneo-mcs. Lysine-rich protein (LRP), which consists of four repeats of 'MGKKKKKKKKKKKKKKKKKKKKKKKKGS' and a V5 tag, was amplified by polymerase chain reaction (PCR) using pLRP101 (9) as a template and inserted into pPEGneo-msc and pCEP4 (Life Technologies, Carlsbad, CA) to create pPEG-LRP and pCMV-LRP, respectively. The sequence of the vector was confirmed (MacrogenUSA, Rockville, MD). Primers used for PCR were as follows: PEG-3 Promoter for pPEG-neo-msc (Forward: CAGAACTAGTAGAAAGAGAAAGAGAATGGGAC; Reverse: AAC AGGATCCGTCCGGTTCGGTTTGC CAAAAGCG), LRP for pPEG-LRP (Forward: CTAAATCG ATCCATCATTTGTACAAAAAAGCAGGCTCCG; Reverse: AGCACCTAGGTTACTAACCGGTACGCGTAGAATCGAG), LRP for pCMV-LRP (Forward: CAGTAAGCTTCCATCAT TTGTACAAAAAAGCAGGCTCCG; Reverse: CACAATCTC GAGTTAC TAACCGGTACGCGTAGAATCGAG).
Establishing a Stable Cell Line Expressing pPEG-LRP and pCMV-LRP
9L cells were transfected separately with pPEG-LRP and pCMV-LRP using Lipofectamine 2000 (Life Technologies, Carlsbad, CA) according to the manufacturer's instructions. 9L PEG-LRP and 9L CMV-LRP were selected by maintaining cells after the transfection in growth medium containing 1 mg/mL of G-418 (Life Technologies, Carlsbad, CA) and 100 μg/mL of Hygromycin B (Corning Cell-gro, Manassas, VA), respectively.
In Vitro CEST MRI
In vitro CEST MRI experiments were performed as previously described (33, 34) with the following modifications. In brief, 1 × 10 7 cells were placed in a 5 mm NMR tube (three tubes from three separate preparations, for each cell type, 9L or 9L PEG-LRP ) and placed within a vertical-bore 11.7T Bruker Avance system (Bruker Biosciences Corp., Billerica, MA) at 37°C. A modified RARE (repetition time/echo time [TR/TE] = 5000/20 ms, RARE factor = 8, 1 mm slice thickness, field of view (FOV) = 1.7 × 1.7 cm, matrix size = 128 × 64, resolution = 0.17 × 0.34 mm, and NA = 2) sequence, including a magnetization transfer (MT) module (B 1 = 3.6 μT/3000 ms) was used to acquire CEST weighted images from −4.4 ppm to +4.4 ppm (step = 0.2 ppm) around the water resonance (0 ppm). For B 0 shift correction of each pixel in the CEST image, the absolute water resonant frequency shift was measured using a modified Water Saturation Shift Reference (WASSR) method (35) , using the same parameters as in CEST imaging except TR = 1500 ms, saturation pulse of 500 ms, B1 = 0.5 μT and a sweep range from −1 ppm to 1 ppm (step = 0.1 ppm).
Animal Model
NOD/SCID/IL2rγ null (NSG) mice were purchased from the Animal Resource Core of the Sidney Kimmel Comprehensive Cancer Center of Johns Hopkins. Mice were anaesthetized by inhaling 1.5% isoflurane/oxygen gas. Small holes were made on the skull at 2 mm lateral to the bregma. 2 × 10 5 cells in 2 μL of media were directly injected into the striatum 3 mm deep from the skull using a 24 gauge Hamilton syringe over 5 min. Animal experiments were performed in accordance with protocols approved by Johns Hopkins Animal Care and Use Committee (ACUC).
In Vivo CEST MRI
Mice with bilateral tumors within striatum (9L and 9L PEG-LRP , n = 8) and (9L and 9L CMV-LRP , n = 1) were used. Data were acquired using a horizontal-bore 11.7 Tesla (T) MRI scanner (Bruker Biospec) equipped with a circular polarized MRI transceiver coil (ID = 23 mm). Seven days after cell transplantation, mice were anesthetized with 1.5% isoflurane and CEST data were obtained as previously described (33, 36) , and with the following parameters: A single 1 mm slice with FOV of 1.6 × 1.6 cm 2 and a 96 × 48 matrix were used, resulting in an in-plane resolution of 0.167 × 0.333 mm. CEST-weighted images were acquired with a modified RARE pulse sequence (TR/TE = 6000/35 ms), using a 3.6 μT/3000 ms saturation pulse from −4.2 to +4.2 ppm (0.2 ppm steps) around the water resonance, which was assigned to be at 0 ppm (total experimental time of 41 min). Pixelbased B 0 correction was used as described before (35) using the same parameters as above except for TR = 1500 ms, B 1 /t sat = 0.5 μT/500 ms, with a sweep range from −1 to +1 ppm (0.1 ppm steps). Mean CEST spectra (Z-spectra) were plotted from a region of interest (ROI) for each tumor and normal brain tissue, after B 0 correction.
CEST Data Processing
Data processing was performed using custom-written scripts in Matlab as described earlier (33) . Mean Z-spectra were used from a ROI for each sample, after B 0 correction for each voxel. MTR asym = 100 × (S-Δω -S Δω )/S 0 was computed at different offsets, Δω. To remove magnetization transfer effects, ΔMTR asym was defined as [MTR asym (tumor)] -[MTR asym (normal brain tissue)], as previously described (37) .
Statistical Analyses
Because a series of frequencies was applied to the same sample in the in vitro CEST MRI, the generalized estimating equation (GEE) approach (38) was used to take into account the correlations across the frequencies when we compared the CEST contrast in 9L and 9L PEG-LRP cells, and P values of the score test were reported. The GEE method was also applied to the comparisons in the in vivo CEST MRI study to account for the correlations arising from the fact that paired data of 9L and 9L PEG-LRP cells were collected from the same mouse and each was measured with a series of frequencies. All the tests were twosided. The analysis was performed using software SAS (version 9.4, Cary, NC)
RESULTS
We first examined whether the PEG-3 promoter was active in the 9L cell line. After transient transfection of 9L cells with pGL3-basic (no promoter control), pPEG-Luc (17), and pCMV-Tri (17), we measured fLuc activity driven by each promoter. The PEG-3 promoter showed activity comparable to one third of that of the CMV promoter in 9L cells ( Fig. 1 ).
To develop cell lines that stably express LRP, we created two mammalian expression vectors for constitutive (pCMV-LRP) and tumor-specific (pPEG-LRP) gene expression. The pCMV-LRP construct was equipped with the CMV promoter and the hygromycin B resistance gene. The pPEG-LRP construct was equipped with the tumor-specific PEG-3 promoter and the neomycin resistance gene. To enhance the relatively weak activity of the PEG-3 promoter compared with the CMV promoter ( Fig. 1) , an SV40 enhancer and an SV40 polyadenylation site were inserted upstream and downstream of the PEG-3 promoter:LRP construct, respectively. After transfecting rat 9L glioma cells with those vectors, we selected cells expressing LRP by maintaining them in media containing hygromycin B and G418 and used surviving cells (9L CMV-LRP and 9L PEG-LRP ) for further study. We performed in vitro CEST MRI to test whether the LRP expressing cells generated CEST contrast. 9L PEG-LRP cells showed increased CEST contrast compared with 9L cells at 3.3-3.9 ppm, the frequency at which the original LRP generated contrast (9) (Fig. 2) .
We then developed murine glioma models to test LRP in vivo. 9L, 9L CMV-LRP , and 9L PEG-LRP cells were capable of forming tumors in the brains of immunocompromised NSG mice, as shown by T2-weighed MRI (Figs. 3a,c ). An increase in CEST contrast was visible in tumors derived from both 9L CMV-LRP and 9L PEG-LRP cells compared with wild-type 9L tumors, as shown in Figs. 3b,d . We imaged a total of eight mice harboring 9L (left) and 9L PEG-LRP (right) in the brain. The average CEST contrast, i.e., ΔMTR asym value, was significantly higher (P < 0.01; n = 8) for tumors derived from cells expressing LRP than from the wild-type 9L tumors at 3.4 ppm (Figs. 3e,f) . These results demonstrate that a CEST reporter gene can be expressed in vivo in a tumor-specific manner and can be used as a tumor-specific biomarker for MR applications.
DISCUSSION
In this preclinical study, we present proof-of-principle for cancer-specific CEST MRI using reporter-based, molecular-genetic imaging. Many reporter genes that produce MR contrast for imaging have been identified and have shown promising characteristics for MR-based molecular-genetic imaging (10, 39, 40) . To apply those reporters to the clinic, they should be selectively expressed in target cells, namely, cancer. Targeted delivery and selective transfection of reporter plasmid is a challenging task, especially for small or micrometastatic lesions. Using a target-specific promoter to control the expression of a reporter at the target is an alternative approach, which we have chosen. The optimal promoter for cancer-specific imaging would be robustly active in a wide variety of human cancers, while remaining inactive or minimally active in normal tissue. We leveraged the well-studied, cancer-specific PEG-3 promoter to drive the expression of the synthetic CEST probe, LRP. We have shown that the PEG-3 promoter is active in all human cancer types tested and is minimally active in the corresponding normal tissues (8, 9, 12) . Because the PEG-3 promoter originated from a rodent genome, and humans do not have the orthologous gene, there is very little possibility of unwanted chromosomal insertion through homologous recombination. In addition, the relatively small size of the PEG-3 promoter (465 base pairs) will be an advantage for designing smaller imaging vectors for improved transfection efficiency (41) .
The LRP does not require additional administration of the probe because the amide protons from the lysine residue are the source of CEST contrast. PEG-3 promoter-driven LRP expression with the SV40 enhancer in animal models of glioma was sufficient to generate detectable CEST contrast.
We designed the pPEG-LRP vector to be suitable for systemic delivery and clinical translation. The vector has the clinically compatible kanamycin resistance marker for the production of the plasmid (42) . Additionally, the pPEG-LRP has a small size of 3575 base pairs, which can enable enhanced transfection efficiency (41) . The present study demonstrated limited CEST contrast from LRP, potentially due to weak promoter activity of tumor-specific PEG-3 promoter. Further modifications of the small pPEG-LRP plasmid to augment the expression of LRP would enhance the sensitivity of detection. For example, a two-step transcriptional amplification system can be introduced to increase the number of LRP molecules expressed (11, 43) . Adding scaffold/matrix attachment regions (S/MARs) to the plasmid will enable prolonged maintenance of the plasmid, resulting in accumulation of LRP within the transfected cancer cells. Also, using longer LRP would enhance CEST contrast. Indeed, CEST imaging using traditional pulse sequences, as in this study, is limited by low sensitivity, manifested by only a few percent change in contrast, especially for biological samples. This is also true for the LRP. As shown above, only a small yet significant (P < 0.01) change was observed. In a similar case, where LRP was used to monitor Oncolytic Virotherapy (44), a significant change was detected; however, it was on the same order of magnitude as described here. Nevertheless, CEST is an evolving field of MRI and new techniques that can improve the sensitivity are constantly under development, including methods for isolating the CEST signal from rapidly exchanging protons such as through length and offset varied saturation (LOVRS) (45), frequency-labeled exchange (FLEX) (46) as well as through separation of the contrast from endogenous contrast from proteins or magnetization transfer contrasts (47) .
The PEG-3 promoter:LRP system enabled cancer-specific imaging using CEST MR in vivo in the rat 9L glioma model. Efforts to extend those findings to experimental models of human cancer in the periphery, with a focus on systemic delivery of the plasmid to detect metastatic disease, are under way. 
